Abstract
Aging is the greatest risk factor for Alzheimer’s disease (AD)1, a pervasive cognitive disorder with unsettled etiology. The precise role of aging in AD, however, remains poorly understood. Accumulating evidence documents the dysregulation of circulating microRNAs (miRNA) separately in aging2,3 and AD4. Considering miRNAs play a role in aging and longevity5,6, we comprehensively test which aging-associated miRNA changes are observed in AD, and change in AD beyond aging in the circulating miRNA network. Here we show that plasma miRNAs in aging are downregulated and preferentially targeted to extracellular vesicle (EV) content, while in AD, miRNAs are further downregulated and of exclusive EV origin. We further show that miRNAs in AD display altered proportions of motifs relevant to their loading into EVs7,8 and secretion propensity9. Considering endosomes play a role in the genesis of EVs10,11 and are compromised early in AD12, these findings implicate endosomal pathology underlying the AD plasma miRNA profile and its potential as a mechanistic AD biomarker. Striking similarities between plasma miRNA profiles in aging and AD further suggest that the AD miRNA network profile reflects a pathological exacerbation of the aging process whereby physiological suppression of AD pathology by plasma miRNAs becomes insufficient.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the European Regional Development Fund No. CZ.02.1.01/0.0/0.0/16_019/0000868 ENOCH(G.B.S.), No. CZ.02.1.01/0.0/0.0/15_003/0000492 MAGNET(G.B.S.), the R01NS095269 (Z.M.) and P30-AGO62429 (R.A.R.) grants.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Motol University Hospital and St. Anne's University Hospital approved the study. The Ethics Committee of Shiley-Marcos Alzheimer's Disease Research Centre and University of California San Diego approved the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
